Over the past two decades, studies of the Southwest Oncology Group have consistently reported stable esophagitis rates despite changing scales with concurrent chest radiotherapy and cisplatin/etoposide regimens. Patient selection has perhaps contributed to increased survival over this period. The Southwest Oncology Group has incorporated surgical questions and advanced the field with a steady use of consistent therapies (ie, cisplatin/etoposide plus radiotherapy of 45 Gy [induction therapy] and cisplatin/etoposide plus at least 61 Gy) in potentially operable or unresectable disease. Further studies examining the addition of either docetaxel or novel agents to such regimens are underway.

中文翻译：

---

西南肿瘤学组：在非小细胞肺癌方面有二十年的经验。

在过去的二十年中，尽管同时进行了胸部放疗和顺铂/依托泊苷治疗方案改变了规模，但西南肿瘤集团的研究始终报告稳定的食管炎发生率。患者的选择也许有助于在此期间增加生存率。西南肿瘤小组已经纳入了外科手术问题，并通过在潜在可手术或不可切除的疾病中稳定使用一致的疗法（即顺铂/依托泊苷加45 Gy放射治疗[诱导疗法]和顺铂/依托泊苷加至少61 Gy）来推进该领域的发展。 。正在研究将多西他赛或新型药物添加到此类方案中的进一步研究。